Liminal BioSciences Inc. LMNL

Healthcare Biotechnology

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.

NDAQ:LMNL - Post by User

Liminal BioSciences Inc. > Plan as recently stated by MGMT

<< Previous

Bullboard Posts

Next >>

Post by GunnerGon Jan 13, 2020 3:33pm

73 Views

Post# 30547821

Plan as recently stated by MGMT

What management is presenting, are separte events in a bulleted list.

Listed point 1 is the "anticipated filing of BLA". No guarantee, management is anticipating its sumbmission. Definition of anticipated - "regard as probable; predict.". Remember, they haven't got the FDA required checks in place and its been two years.

Listed point 2, "expected completion" of partnership. No guarantee of a partnership they are hopeful to get a deal.

Also, you failed to highlight the most critical part of point 2; "if approval received". Management is stating a partnership is hopeful; if the FDA approval is received.

Point 1 is a separate event, ie filing BLA.

Point 2 is another event, totally separate from the first.

Key Corporate and R&D Priorities for 2020

Anticipated filing of an amended BLA with FDA for Ryplazim for the treatment of congenital plasminogen deficiency in the first half of the year
Expected completion of a global marketing partnership for Ryplazim, and preparation for commercial launch of Ryplazim in the United States, if approval is received